
# On the use of PRESAGE detectors for the dosimetry of helical TomoTherapy small fields

A. Moutsatsos<sup>1</sup>, E. Pantelis<sup>1,2</sup>, C. Antypas<sup>2</sup>,
L. Petrokokkinos<sup>1</sup>, E. P. Pappas<sup>1</sup>, E. Zoros<sup>1</sup>,
P. Pantelakos<sup>2</sup>,
E. Georgiou<sup>1</sup> and P. Karaiskos<sup>1</sup>

<sup>1</sup>Medical Physics Laboratory, Medical School, National and Kapodistrian University of Athens, Greece

<sup>2</sup>CyberKnife & TomoTherapy Department, Iatropolis Clinic, Ethnikis Antistasis 54-56, Chalandri, Athens, Greece



# Modern Radiotherapy <u>Techniques</u>

- √ Use of small fields (or beams)
- ✓ Steep dose gradients
- √ 3D, complex-shaped dose dist.


#### **Verification**

- √ Affects clinical outcome
- ✓ Dosimetic and Geometric verification in 3D
- ✓ No ideal dosimeter → Multi-Detector approach including research dosimeters



<u>Purpose:</u> To apply 3D PRESAGE dosimetry for the verification of helical TomoTherapy dose delivery for a clinical prostate plan, and assess possible corrections of the A1SL ion-chamber response for a Plan-Class-Specific-Reference irradiation field (PCSR).







- ➤ In-house constructed PMMA phantom
- ➤ Adequate inserts permitting :
- - ✓ 3D PRESAGE dosimetry
  - ✓ Film dosimetry (EBT2, Gafchromic) – –
  - ✓ A1SL (IBA) ion chamber dosimetry













#### Methods 1: Plan-Class-Specific Reference field (f<sub>PCSR</sub>)

- O TG-148 recommendations:
  - ✓ 2.5 cm collimator
  - ✓ 0.287 pitch
  - ✓ 2.0 Modulation Factor
  - ✓ Homogenous Dose distribution (**4 Gy**) (Cylinder: 5 cm long and 5 cm diam.)
- o pre-irradiation CT-scan
- $\circ$  A1SL:  $k_{Q_{ref},Q_0} = 0.996$







- - ► A1SL insert



#### Methods 2: Prostate clinical plan

- ✓ 3 x 2.4 Gy to Prostate
- ✓ 3 x 2.9 Gy to Seminal vessels
- ✓ 2.5 cm collimator
- ✓ 0.287 pitch
- ✓ 2.4 actual MF









#### **Results:** PCSR plan

Detector	D <sub>PCSR</sub> (Gy)
PRESAGE	3.98±0.10
EBT-2	4.03±0.12
A1SL	4.09±0.05
$k_{Q_{ref},Q_{PCSR}}^{f_{ref},f_{PCSR}}$	0.98a±0.03




a Although within uncertainties, A1SL was found to overestimate **D**<sub>PCSR</sub> by 2% - in accordance with Gago-Arias et al. {MedPhys, **39**, 1964 (2012); doi: 10.1118/1.3692181}





#### **Results:**

Prostate clinical plan



1 EUROPEAN CONGRESS OF MEDICAL PHYSICS
September 1-4, 2016
Eugenides Foundation, Athens-Greece

A1SL:  $(7.21 \pm 0.03)$  Gy

#### **Conclusion**

Besides water equivalence and exquisite spatial resolution, necessitated for small field dosimetry and determination of appropriate correction factors, PRESAGE dosimeters offer the advantage of 3D dose verification.

